ArticleScientific reports2025
Impact of smoking and physical activity on cardiovascular outcomes in type 2 diabetes across steatotic liver disease categories.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interrelationships Between Key Cardiovascular Risk Factors, Chronic Kidney Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease.Current cardiology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the effect of smoking and regular physical activity (PA) on the composite risk of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM) across different steatotic liver disease (SLD) categories. We analyzed data for 1,921,310 patients with T2DM aged 20 years and older. The participants were categorized by SLD status, with hepatic steatosis (fatty liver index ≥ 30). Among current smokers, the adjusted hazard ratios (HR) for composite CVD events significantly increased from the no steatosis to metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related steatotic liver disease (MetALD), and alcohol-related liver disease (ALD) groups, with the highest HR observed in the ALD group (aHR, 2.14; 95% confidence interval [CI], 2.04-2.24). The ALD group without regular PA had the highest risk of composite CVD events (aHR, 1.33; 95% CI, 1.28-1.38). The highest risk of composite CVD events was found among current smokers without regular PA, with the aHR increasing in a stepwise manner from no steatosis to MASLD, MetALD, and ALD groups, with the latter showing the highest risk. Smoking and physical inactivity significantly increased the CVD risk in patients with T2DM, with the highest risk in the ALD group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.